|324.60||-10.14||-3.03%||Vol 676.42K||1Y Perf 0.45%|
|May 16th, 2022 16:00 DELAYED|
|- -||5.39 1.66%|
|Target Price||537.40||Analyst Rating||Strong Buy 1.20|
|Potential %||65.56||Finscreener Ranking||★★ 44.71|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★ 40.08|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★★★★+ 63.10|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Price Range Ratio 52W %||6.16||Earnings Rating||Neutral|
|Market Cap||31.85B||Earnings Date||28th Apr 2022|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Sell|
|10 Years||3 015.16%|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||0.50|
|EPS Growth Next 5 Years %||17.40|
|Avg. Weekly Volume||1.08M|
|Avg. Monthly Volume||801.44K|
|Avg. Quarterly Volume||794.93K|
DexCom Inc. (NASDAQ: DXCM) stock closed at 324.6 per share at the end of the most recent trading day (a -3.03% change compared to the prior day closing price) with a volume of 676.42K shares and market capitalization of 31.85B. Is a component of S&P 500, NASDAQ 100, Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 6400 people. DexCom Inc. CEO is Kevin R. Sayer.
The one-year performance of DexCom Inc. stock is 0.45%, while year-to-date (YTD) performance is -39.55%. DXCM stock has a five-year performance of 377%. Its 52-week range is between 302.61 and 659.4518, which gives DXCM stock a 52-week price range ratio of 6.16%
DexCom Inc. currently has a PE ratio of 160.90, a price-to-book (PB) ratio of 15.00, a price-to-sale (PS) ratio of 12.38, a price to cashflow ratio of 69.40, a PEG ratio of 2.32, a ROA of 4.25%, a ROC of 6.34% and a ROE of 9.81%. The company’s profit margin is 8.26%, its EBITDA margin is 15.10%, and its revenue ttm is $2.57 Billion , which makes it $26.21 revenue per share.
Of the last four earnings reports from DexCom Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $0.50 for the next earnings report. DexCom Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for DexCom Inc. is Strong Buy (1.2), with a target price of $537.4, which is +65.56% compared to the current price. The earnings rating for DexCom Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
DexCom Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
DexCom Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 16.25, ATR14 : 22.62, CCI20 : -95.61, Chaikin Money Flow : -0.26, MACD : -39.13, Money Flow Index : 18.24, ROC : -21.45, RSI : 27.84, STOCH (14,3) : 17.06, STOCH RSI : 0.84, UO : 33.90, Williams %R : -82.94), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of DexCom Inc. in the last 12-months were: Andrew K. Balo (Sold 18 516 shares of value $9 303 509 ), Barbara E. Kahn (Sold 2 766 shares of value $1 219 757 ), Barry J. Regan (Sold 5 208 shares of value $2 991 322 ), Chad Patterson (Sold 4 858 shares of value $2 181 568 ), Donald Abbey (Sold 1 263 shares of value $683 747 ), Jake Leach (Sold 24 018 shares of value $9 671 973 ), Jay S. Skyler (Sold 20 000 shares of value $8 527 404 ), Jereme M. Sylvain (Sold 1 594 shares of value $851 045 ), Kevin R. Sayer (Sold 48 191 shares of value $23 402 717 ), Mark G. Foletta (Sold 960 shares of value $559 458 ), Matthew Vincent Dolan (Sold 2 186 shares of value $928 359 ), Nicholas Augustinos (Sold 3 306 shares of value $1 795 880 ), Patrick Michael Murphy (Sold 2 487 shares of value $1 238 087 ), Paul R. Flynn (Sold 2 004 shares of value $1 106 135 ), Quentin S. Blackford (Sold 18 562 shares of value $10 165 281 ), Richard A. Collins (Sold 1 500 shares of value $970 575 ), Sadie Stern (Sold 2 051 shares of value $1 278 335 ), Shelly Ramasamy Selvaraj (Sold 8 174 shares of value $4 137 968 ), Steven R. Pacelli (Sold 6 249 shares of value $3 055 772 ), Sumi Shrishrimal (Sold 807 shares of value $380 775 )
Sat, 30 Apr 2022 03:53 GMT Dexcom (DXCM) Gets a Buy Rating from Robert W. Baird- TipRanks. All rights reserved.
Sat, 12 Feb 2022 04:20 GMT Analysts Offer Insights on Healthcare Companies: Dexcom (DXCM) and Illumina (ILMN)- TipRanks. All rights reserved.
Tue, 11 Jan 2022 15:24 GMT Dexcom (DXCM) Received its Third Buy in a Row- TipRanks. All rights reserved.
Mon, 10 Jan 2022 13:45 GMT Dexcom (DXCM) Gets a Hold Rating from BTIG- TipRanks. All rights reserved.
Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
eToro USA LLC does not offer CFDs and makes no representation and assumes no liability as to the accuracy or completeness of the content of this publication, which has been prepared by our partner utilizing publicly available non-entity specific information about eToro. Your capital is at risk.
This could take some time, please wait.